You are here

gene therapy

Sanofi to ax 466 jobs, step up focus on cancer, gene therapy R&D

Fierce Biotech

Thu, 06/20/19 - 09:56 am

immuno-oncology

'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops

Endpoints

Wed, 06/19/19 - 10:29 am

Bristol-Myers Squibb

What Bluebird Bio Gets Wrong In Pricing For Its $1.8 Million Drug

Forbes

Wed, 06/19/19 - 09:55 am

beta thalassemia

Rocket begins patient dosing in phase 1 trial of RP-A501 in Danon disease

Pharmaceutical Business Review

Wed, 06/19/19 - 09:52 am

Rocket Pharmaceuticals

Bluebird delays gene therapy launch to 2020, citing manufacturing tweaks

Biopharma Dive

Tue, 06/18/19 - 11:57 am

drug manufacturing

Sanofi Genzyme deserts gene therapy developer Voyager Therapeutics

Endpoints

Mon, 06/17/19 - 11:26 pm

Voyager Therapeutics

bluebird offers installment payments for Zynteglo gene therapy

Pharmaforum

Mon, 06/17/19 - 12:25 pm

outcome-based pricing

beta thalassemia

Cue the M&A chatter: UniQure is scouting for a buyout deal as gene therapy field sizzles — report

Endpoints

Sun, 06/16/19 - 11:19 pm

Gene therapy costs, manufacturing keeping CBER head 'up at night'

Biopharma Dive

Thu, 06/13/19 - 09:47 pm

drug manufacturing

The gene therapy era has arrived. So have the challenges.

Biopharma Dive

Sun, 06/9/19 - 01:43 pm

Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?

Motley Fool

Sun, 06/9/19 - 01:41 pm

Duchenne Muscular Dystrophy

Vertex Pharmaceuticals

CRISPR Therapeutics

Vertex sets sights on DMD gene therapy, joining crowded field

Biopharma Dive

Fri, 06/7/19 - 10:17 am

Vertex Pharmaceuticals

CRISPR Therapeutics

Patients, payers await pricing plans for bluebird's first approved gene therapy

BioCentury

Tue, 06/4/19 - 11:04 am

beta thalassemia

Bluebird Bio’s Gene Therapy for Blood Disease Wins European Approval

Xconomy

Mon, 06/3/19 - 07:50 pm

beta thalassemia

Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous?

Motley Fool

Fri, 05/31/19 - 11:53 pm

Amicus widens UPenn gene therapy collaboration

Biopharma Dive

Wed, 05/29/19 - 10:35 pm

Amicus Therapeutics

How BioMarin May Revolutionize the Hemophilia Treatment Market

Motley Fool

Tue, 05/28/19 - 11:25 pm

Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range

Yahoo/Reuters

Thu, 05/23/19 - 09:48 am

UniQure snags patents on Huntington's gene therapy as it preps for the clinic

Biopharma Dive

Wed, 05/22/19 - 09:06 pm

Huntington's disease

clinical trials

David Hallal brings his first cell therapy company into the fold, and it's tied to a major league financing deal

Endpoints

Wed, 05/22/19 - 09:53 am

Pages